Statements (28)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
|
| gptkbp:approvalYear |
2001
|
| gptkbp:ATCCode |
gptkb:M05BA08
|
| gptkbp:brand |
gptkb:Aclasta
gptkb:Zomera |
| gptkbp:CASNumber |
165800-06-6
|
| gptkbp:chemicalFormula |
C5H10N2O7P2
|
| gptkbp:contraindication |
severe renal impairment
|
| gptkbp:drugClass |
bisphosphonate
|
| gptkbp:genericName |
gptkb:zoledronic_acid
|
| https://www.w3.org/2000/01/rdf-schema#label |
Zometa
|
| gptkbp:indication |
gptkb:Paget's_disease_of_bone
multiple myeloma bone metastases from solid tumors |
| gptkbp:legalStatus |
prescription only
|
| gptkbp:manufacturer |
gptkb:Novartis
|
| gptkbp:mechanismOfAction |
inhibits osteoclast-mediated bone resorption
|
| gptkbp:molecularWeight |
272.09 g/mol
|
| gptkbp:pregnancyCategory |
D (US)
|
| gptkbp:routeOfAdministration |
intravenous
|
| gptkbp:sideEffect |
hypocalcemia
flu-like symptoms osteonecrosis of the jaw renal toxicity |
| gptkbp:usedFor |
prevention of skeletal-related events in patients with bone metastases
treatment of hypercalcemia of malignancy |
| gptkbp:bfsParent |
gptkb:Novartis
|
| gptkbp:bfsLayer |
4
|